Cost of septic and aseptic revision total knee arthroplasty: a systematic review

Okafor, Charles; Hodgkinson, Brent; Nghiem, Son; Vertullo, Christopher; Byrnes, Joshua

doi:10.1186/s12891-021-04597-8

BMC Musculoskeletal Disorders

Table 1 Characteristics of included studies

From: Cost of septic and aseptic revision total knee arthroplasty: a systematic review

Author, year & reference	Country	Interest –case sample size	Age (CI) [SD]	Sex proportion	Cause of revision	Study perspective	Time horizon of observation (months)	Type of Economic Evaluation	Comparator	Study design	Cost Component
Adeyemi et al., 2019 [20]	United States	1140	64.8	Male, 42.1%; Female, 57.9%	Infection	HCP	12	COI	Non-SSI. RTHA	Cohort	Direct cost
Alp et al., 2016 [40]	Turkey	11	65	Male, 29.4%; Female, 70.6%	Infection	HCP	24	COI	Non-SSI	Cross sectional	Direct cost
Bosco III et al., 2014 [21]	United States	118	N/A	N/A	N/A	HCP. payer	48	COI	THA; TKA; RTHA	Cohort	Direct cost
Bozic et al., 2010 [22]	United States	60,355	65.8	Male, 42.6%; Female, 57.4%	Infection; mechanical loosening; implant fracture	HCP	15	COI	N/A	Cross sectional	Direct cost
Burns et al., 2006 [41]	Canada	73	N/A	N/A	N/A	Payer	24	CEA	PTKA	Cohort	Direct cost
Clair et al., 2016 [23]	United States	24	65	Male, 29.2%; Female, 70.8%	N/A	HCP	12	COI	RTHA	Cross sectional	Direct cost
Dal-Paz et al., 2010 [42]	Brazil	34	67.1 ± 12.0	Male, 32.4%; Female, 67.6%	Infection	HCP	24	COI	N/A	Cross sectional	Direct cost
Efremov et al., 2019 [43]	Italy	30	71.2 ± 6.3	Male, 53%; Female, 47%	Infection	HCP	30.4	COI	RTHA	Cohort	Direct cost
Gow et al., 2016 [44]	New Zealand	3	69 (49–78)	Male, 72.2%; Female, 27.8%	Infection	HCP	12	COI	Non-SSI	Case-control	Direct cost
Haenle et al., 2012 [45]	Germany	28	71.7	Male, 28.6%; Female, 71.4%	Infection	HCP	48	COI	PTKA	Case-control	Direct cost
Herbert et al., 1996 [19]	United States	20	65	N/A	Aseptic; Infection	HCP	36	COI	PTKA	Cross sectional	Direct cost
Holinka et al., 2018 [48]	Czech Republic	20	68.5 (55–82)	N/A	Aseptic; Infection	Payer	N/A	COI	PTKA	Cross sectional	Direct cost
Iorio et al., 1999 [24]	United States	32	N/A	N/A	N/A	HCP	24	COI	PTKA	Cross sectional	Direct cost
Kallala et al., 2015 [50]	United Kingdom	168	65.6	Male, 46.43%; Female, 53.57%	Aseptic; Infection	Patient	84	COI	Aseptic revision	Cross sectional	Direct cost
Kamath et al., 2015 [25]	United States	301,718	65.7 (65–69)	Male, 50.1%; Female, 49.9%	Infection	HCP	64	COI	RTHA	Cross sectional	Direct cost
Kapadia et al., 2014 [26]	United States	21	N/A	N/A	Infection	HCP	60	COI	PTKA	Case-control	Direct cost
Kasch et al., 2017 [46]	Germany	106	66.8 [9.5]	Male, 35.8%; Female, 64.2%	Aseptic; Infection	HCP	39	COI	Aseptic revision	Cross sectional	Direct cost
Kurtz et al., 2008 [27]	United States	N/A	69.5	N/A	Infection	HCP	180	COI	RTHA; PTKA; PTHA	Cross sectional	Direct cost
Kurtz et al., 2012 [28]	United States	105,068	64.5	N/A	Infection	HCP	108	COI	RTHA	Cross sectional	Direct cost
Lavernia et al., 1995 [29]	United States	24	68.0	Male, 29.2%; Female, 70.8%	N/A	HCP	48	COI	PTHA; PTKA; RTHA	Cross sectional	Direct cost
Lavernia et al., 2006 [30]	United States	100	63.5	Male, 28.6%; Female, 71.4%	Aseptic loosening; Infection	HCP	108	COI	N/A	Cross sectional	Direct cost
Li Y. et al., 2013 [31]	United States	18,677	74.6 [6.5]	Male, 38.8%; Female, 61.2%	N/A	Payer	12	COI	PTKA	Cross sectional	Direct cost
Musil et al., 2019 [49]	Czech Republic	24		Male, 45.8%; Female, 54.2%	Infection	HCP	96	COI	N/A	Cross sectional	Direct cost
Nichols et al., 2016a [32]	United States	25,354	63.3 [10.5]	Male, 42.3%; Female, 57.7%	N/A	Payer + patient	60	COI	PTKA; PTHA; RTHA	Cross sectional	Direct cost
Nichols et al., 2016b [33]	United States	32,494	65.26 [10.98]	Male, 40.5%; Female, 59.5%	N/A	Payer	78	COI	PUTKA; SBTKA	Cross sectional	Direct cost
Oduwole et al., 2010 [51]	Republic of Ireland	179	71.5	Male, 35%; Female, 65%	Infection; Aseptic	HCP	120	COI	Aseptic revision	Cross sectional	Direct cost
Parvizi et al., 2010 [34]	United States	216	62.4	Male, 48.8%; Female, 51.2%	Infection	HCP	132	COI	Methicillin sensitive cases	Cross sectional	Direct cost
Puhto et al., 2019 [52]	Finland	26	69 (38–91)	Male, 49.5%; Female, 50.5%	Infection; Aseptic	HCP	36	COI	Primary TKA	Cohort	Direct cost
Reeves et al., 2018 [35]	United States	46,836	69.1	Male, 31.1%; Female, 68.9%	Prosthetic fracture; non-fracture cause	HCP	12	COI	PPFX; ORIF; PTKA	Cohort	Direct cost
Ritter et al., 1996 [36]	United States	26	N/A	N/A	N/A	Payer	N/A	COI	PTKA; PTHA; RTHA	Cross sectional	Direct cost
Sculco, 1995 [37]	United States	N/A	N/A	N/A	N/A	HCP	N/A	COI	N/A	Cross sectional	Direct cost
Sousa et al., 2018 [53]	Portugal	29	68.3 (39–80)	Male, 32.2%; Female, 67.7%	Infection	HCP	24	COI	PTKA; PTHA; RTHA	Case-control	Direct cost
Waddell et al., 2016 [38]	United States	70	N/A	N/A	Infection	HCP	56	COI	RTHA	Cross sectional	Direct cost
Weber et al., 2018 [47]	Germany	68	67.9 [9.2]	Male, 38.2%; Female, 61.8%	N/A	HCP	60	COI	PTHA; PTKA; RTHA	Case-control	Direct cost
Yi et al., 2015 [39]	United States	79	≥ 65	Male, 43%; Female, 57%	Infection	Payer	96	COI	PTHA; PTKA; RTHA	Cohort	Direct cost
Yao et al., 2020 [9]	United States	266	65 (54–76)	Male, 61%; Female, 39%	Infection; Aseptic	HCP + Payer	84	COI	Non-SSI	Cross sectional	Direct cost
Iqbal et al., 2020 [10]	Pakistan	32	61.3 (55.4–67.2)	N/A	Infection	HCP	60	COI	PTKA	Case-control	Direct cost

N/A Not available, SD Standard deviation, HCP Healthcare provider, COI Cost of illness, CEA Cost-effectiveness analysis, SSI Surgical site infection, TKA Total knee arthroplasty, THA Total hip arthroplasty, RTHA Revision total hip arthroplasty, PTKA Primary total knee arthroplasty, PTHA Primary total hip arthroplasty, PUTKA Primary unilateral total knee arthroplasty, SBTKA Simultaneous bilateral total knee arthroplasty, TJA Total joint arthroplasty, PPFX Periprosthetic fracture, ORIF Open reduction internal fixation

Back to article page

ISSN: 1471-2474

Contact us

Submission enquiries: bmcmusculoskeletaldisorders@biomedcentral.com
General enquiries: ORSupport@springernature.com